Abstract
A Case to Support the Continued Use of Rifampin in Clinical Drug-Drug Interaction Studies.
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have